FGEN Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
My Notes
Capture your thoughts, links and company narrative
FibroGen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.58 |
| 52 Week High | US$2.93 |
| 52 Week Low | US$0.18 |
| Beta | 0.82 |
| 1 Month Change | 49.38% |
| 3 Month Change | 42.47% |
| 1 Year Change | -36.30% |
| 3 Year Change | -95.90% |
| 5 Year Change | -98.68% |
| Change since IPO | -97.37% |
Recent News & Updates
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 26% Share Price Rise
Dec 25
Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding
Oct 29Recent updates
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 26% Share Price Rise
Dec 25Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding
Oct 29The Market Doesn't Like What It Sees From FibroGen, Inc.'s (NASDAQ:FGEN) Revenues Yet As Shares Tumble 65%
Aug 19Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 44% Pounding
Jul 04FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward
Jun 06Pamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial Strains
May 28Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet
May 07FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Mar 22There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise
Feb 05FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%
Dec 22A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)
Nov 24Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)
Apr 18Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?
Feb 13The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts
Nov 12Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?
Oct 09FibroGen completes patient enrollment for Roxadustat to treat anemia in patients
Aug 26FibroGen Q2 2022 Earnings Preview
Aug 05Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?
Jul 06Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?
Mar 31Time To Worry? Analysts Are Downgrading Their FibroGen, Inc. (NASDAQ:FGEN) Outlook
Mar 05Is FibroGen (NASDAQ:FGEN) Using Debt In A Risky Way?
Dec 08Shareholder Returns
| FGEN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 63.7% | 2.1% | 2.8% |
| 1Y | -36.3% | -3.8% | 24.5% |
Return vs Industry: FGEN underperformed the US Biotechs industry which returned -3.8% over the past year.
Return vs Market: FGEN underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| FGEN volatility | |
|---|---|
| FGEN Average Weekly Movement | 14.5% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: FGEN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: FGEN's weekly volatility has decreased from 21% to 15% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 486 | Thane Wettig | www.fibrogen.com |
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.
FibroGen, Inc. Fundamentals Summary
| FGEN fundamental statistics | |
|---|---|
| Market cap | US$50.24m |
| Earnings (TTM) | -US$121.79m |
| Revenue (TTM) | US$180.02m |
0.3x
P/S Ratio-0.5x
P/E RatioIs FGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FGEN income statement (TTM) | |
|---|---|
| Revenue | US$180.02m |
| Cost of Revenue | US$195.17m |
| Gross Profit | -US$15.16m |
| Other Expenses | US$106.64m |
| Earnings | -US$121.79m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.21 |
| Gross Margin | -8.42% |
| Net Profit Margin | -67.66% |
| Debt/Equity Ratio | -45.1% |
How did FGEN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 23:52 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
FibroGen, Inc. is covered by 15 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Kennen MacKay | Credit Suisse |
| Matthew Keller | H.C. Wainwright & Co. |